Jennifer Zachary - Merck Executive Vice President, General Counsel

MRK -- USA Stock  

Quarterly Earning Report: October 29, 2019  

  President
Ms. Jennifer Zachary is Executive Vice President, General Counsel of the Company, effective April 16, 2018. Zachary is currently a partner at Covington Burling in the firm food, drug, and device practice group where she advises a wide range of manufacturers and industry trade associations on FDA requirements for the development, manufacture, and distribution of prescription and overthecounter drugs, biologics, and medical devices. Zachary began her career in FDA Office of Chief Counsel, where she served as an Associate Chief Counsel for Enforcement from 2005 to 2011. Zachary also served as a Special Assistant U.S. Attorney in the Civil Division of the U.S. Attorney Office for the District of Columbia.
Age: 40  President Since 2018      
908-740-4000  http://www.merck.com

Management Efficiency

The company has Return on Asset of 0.13 % which means that on every $100 spent on asset it made $0.13 of profit. This is way below average. In the same way, it shows return on shareholders equity (ROE) of 0.29 % implying that it generated $0.29 on every 100 dollars invested.
The company has 27.59 B in debt with debt to equity (D/E) ratio of 99.4 . This implies that the company may be unable to create cash to meet all of its financial commitments. Merck has Current Ratio of 1.19 demonstrating that it may not be capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives

PRESIDENT Since

Jeffrey SimmonsEli Lilly And Company
2008
Joshua SmileyEli Lilly And Company
2018
Kathrin JansenPfizer
2015
Tadashi MotoiHutchison China MediTech Limite
2015
Susan MahonyEli Lilly And Company
2011
Luke MielsGlaxoSmithKline PLC
2017
Leigh PuseyEli Lilly And Company
2017
Sean BohenAstrazeneca PLC
2015
Freda LewisHallPfizer
2010
Ruud DobberAstrazeneca PLC
2019
Adam DubowBristol Myers Squibb Company
2018
Christopher BoernerBristol Myers Squibb Company
2018
Enrique ConternoEli Lilly And Company
2017
Barton PetersonEli Lilly And Company
2009
Emmanuel BlinBristol Myers Squibb Company
2016
Paul AutenriedBristol Myers Squibb Company
2016
David FredricksonAstrazeneca PLC
2017
Katarina AgeborgAstrazeneca PLC
2011
Michael SneedJohnson Johnson
2018
James BradnerNovartis AG
2016
Bill LouvGlaxoSmithKline PLC
2013

Entity Summary

It operates in Pharmaceutical, Animal Health, Healthcare Services, and Alliances segments. Merck Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. Merck operates under Drug Manufacturers - Major classification in USA and is traded on BATS Exchange. It employs 69000 people.Merck Company (MRK) is traded on BATS Exchange in USA. It is located in 2000 Galloping Hill Road and employs 69,000 people. Merck Company was previously known as Merck Co and was traded on BATS Exchange under the symbol SGP. Merck is listed under Pharmaceutical Products category by Fama And French industry classification.

Merck Leadership Team

Thomas Glocer, Independent Director
Craig Thompson, Independent Director
Jennifer Zachary, Executive Vice President, General Counsel
Rochelle Lazarus, Independent Director
Michael Rosenblatt, Executive Vice President Chief Medical Officer
Wendell Weeks, Independent Director
Michael Holston, Executive Vice President Chief Ethics and Compliance Officer
Paul Rothman, Independent Director
Mary Coe, Independent Director
Adele Ambrose, Senior Vice President Chief Communications Officer
Joseph Romanelli, IR Contact Officer
Mirian GraddickWeir, Executive Vice President - Human Resources
Peter Wendell, Independent Director
John Noseworthy, Independent Director
Leslie Brun, Lead Independent Director
Julie Gerberding, Executive Vice President and Chief Patient Officer, Strategic Communications, Global Public Policy and Population Health
Inge Thulin, Independent Director
Pamela Craig, Independent Director
Patricia Russo, Independent Director
Willie Deese, Executive Vice President and Presidentident - Merck Manufacturing Division
Rita Karachun, Principal Accounting Officer, Sr. VP of Fin. and Global Controller
Robert Davis, Executive Vice President, Global Services, Chief Financial Officer
Robert Kidder, Independent Director
Thomas Cech, Independent Director
Michael Nally, Executive Vice President, Chief Marketing Officer
Clark Golestani, CIO and Executive VP
William Harrison, Lead Independent Director
Roger Perlmutter, Executive Vice President and Presidentident - Merck Research Laboratories
Ashley Watson, Senior Vice President Chief Ethics and Compliance Officer
Steven Mizell, Executive Vice President, Chief Human Resources Officer, Human Resources
Jim Scholefield, Executive Vice President, Chief Information and Digital Officer
Sanat Chattopadhyay, Executive Vice President and President - Merck Manufacturing Division
Adam Schechter, President of Global Human Health and Executive VP
Carlos Represas, Independent Director
Richard DeLuca, Executive Vice President and Presidentident - Merck Animal Health
Kenneth Frazier, Chairman of the Board, President, Chief Executive Officer
Frank Clyburn, Executive Vice President, Chief Commercial Officer

Stock Performance Indicators

Did you try this?

Run Competition Analyzer Now

   

Competition Analyzer

Analyze and compare many basic indicators for a group of related or unrelated entities
All  Next Launch Module

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see also Stocks Correlation. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.
Search macroaxis.com